01852nas a2200265   4500000000100000008004100001653001200042653001900054653001100073100002100084700002200105700002100127700002200148700002100170700002000191700001500211700002100226700002300247700001400270700002000284700001800304245011900322520113100441022001401572       2016                            d10aleprosy10aSusceptibility10aMexico1 aAguilar-Medina M1 aEscamilla-Tilch M1 aFrías-Castro LO1 aRomero-Quintana G1 aEstrada-Garcia I1 aEstrada-Parra S1 aGranados J1 aArambula Meraz E1 aSánchez-Schmitz G1 aKhader SA1 aRangel-Moreno J1 aRamos-Payan R00aHLA Alleles are Genetic Markers for Susceptibility and Resistance towards Leprosy in a Mexican Mestizo Population.3 a<p>Despite the use of multidrug therapy, leprosy remains endemic in some countries. The association of several human leucocyte antigen (HLA) alleles and gene polymorphisms with leprosy has been demonstrated in many populations, but the major immune contributors associated to the spectrum of leprosy have not been defined yet. In this study, genotyping of HLA-A, -B, -DR, and -DQ alleles was performed in leprosy patients (n = 113) and control&nbsp;subjects (n = 117) from the region with the highest incidence for the disease in México. The odds of developing leprosy and lepromatous subtype were 2.12- and 2.74-fold higher in carriers of HLA-A*28, and 2.48- and 4.14-fold higher for leprosy and dimorphic subtype in carriers of DQB1*06. Interestingly, DQB1*07 was overrepresented in healthy individuals, compared to patients with leprosy (OR = 0.08) and the lepromatous subtype (OR = 0.06). These results suggest that HLA-A*28 is a marker for predisposition to leprosy and the lepromatous subtype and DQB1*06 to leprosy and the dimorphic subtype, while DQB1*07 might be a resistance marker in this Mestizo population.</p>
  a1469-1809